New Real-World Data from Medtronic Global SYMPLICITY Registry Show Renal Denervation Lowered Blood Pressure in Patients with Hypertension Out to Three Years
Regardless of the Number of Anti-Hypertensive Medications Prescribed, Majority of Patients with Highest BP Showed Significant Drops at Three Years
DUBLIN, June 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today reported new data from the Global SYMPLICITY Registry (GSR), which showed that renal denervation (RDN) with the Medtronic Symplicity™ Renal Denervation System significantly reduced blood pressure (BP) in uncontrolled hypertension patients out to three years independent of anti-hypertension medication burden. The data were presented virtually as part of the PCR e-Course 2020.
The study showed RDN led to significant and clinically meaningful reductions in blood pressure that were sustained out to three years post-procedure (17 mmHg OSBP (office systolic blood pressure)), with more patients achieving BP below 140 mmHg, while those at very high BP levels experiencing drops into lower risk BP ranges. The number of patients at the very highest BP level – greater than 180 mmHg systolic at baseline – dropped by two-thirds at three years. Additionally, the number of patients who had reported office systolic BP less than 140 mmHg – a more controlled level of BP – increased from 13 percent at baseline to 39 percent at three years. The BP drops occurred while patients were prescribed an average of four or more anti-hypertensive medications, which remained unchanged over three years. The absence of increase in medications suggest that RDN’s effect was independent of anti-hypertensive medication burden. RDN continued to show a strong safety profile at three years with an incidence of renal artery stenosis of 0.3 percent, which is within the expected range for patients with hypertension not undergoing denervation.
“In the largest real-world study of patients receiving renal denervation, we are seeing significant and clinically meaningful reductions in both office and 24-hr blood pressure sustained out to three years post-procedure, which demonstrates the durability of RDN,” said Felix Mahfoud, M.D., cardiologist at Saarland University Medical Center in Homburg, Germany, who presented the data during the meeting. “These data reinforce that RDN is a viable, complementary option with positive effects on hypertensive patients without requiring an increase in medication burden over time.”
The Global SYMPLICITY Registry is the largest study documenting the long-term safety and effectiveness of the Medtronic renal denervation systems in a real-world setting in patients with uncontrolled hypertension. To date, the registry has enrolled more than 2,860 patients treated with RDN and includes three-year follow-up for more than 2,500 patients. The data presented at PCR closely mirror a recent manuscript of GSR data published in JACC, which reported that RDN showed lasting results in a variety of high-risk patients, including those with diabetes, chronic kidney disease (CKD), isolated systolic hypertension (ISH), or resistant hypertension.
"Following the positive SPYRAL HTN-OFF MED Pivotal data presented at ACC, these new data provide additional evidence on the safety and efficacy of renal denervation to help manage uncontrolled hypertension, with study patients experiencing meaningful blood pressure reductions out to several years,” said Dave Moeller, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic. "As the body of clinical evidence supporting renal denervation grows, we are encouraged by the outcomes observed in both controlled clinical trials and real-world practice.”
Hypertension is the single largest contributor to cardiovascular death; it dramatically increases risk of heart attack, stroke, heart failure, and kidney failure. The annual direct costs of hypertension are estimated at $500 billion worldwide. It is estimated that almost 20 percent of patients are completely non-adherent to oral medications while nearly half are partially non-adherent, highlighting the need for alternative treatment options.
In addition to the Global SYMPLICITY Registry, the Medtronic SPYRAL HTN Global Clinical Program includes the SPYRAL HTN-OFF MED PIVOTAL and SPYRAL HTN-ON MED Trials, both prospectively powered, randomized, sham-controlled studies evaluating patients with uncontrolled blood pressure in the absence and presence of prescribed anti-hypertensive medications respectively. Approved for commercial use in more than 50 countries around the world, the Symplicity Spyral™ system is limited to investigational use in the United States.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
ISO Introduces Optional Endorsement for Damage to Underground Utility Lines16.7.2020 16:04:55 CEST | Press release
New Option Addresses Expenses Not Covered by Standard Homeowners Policies Jersey City, NJ, July 16, 2020 (GLOBE NEWSWIRE) -- ISO, a Verisk (Nasdaq:VRSK) business, has launched a new homeowners endorsement to address damage to underground utility lines, a risk that isn’t always handled by municipalities or covered in standard homeowners insurance policies. The new endorsement for the ISO Homeowners Program can be used to provide coverage related to underground pipes, wires, and some buried equipment from a range of causes, including explosions, tree root growth, and wear and tear. “Claims arising from buried utilities often come as a surprise because deterioration is hidden until a loss of service occurs,” said Doug Caccese, president of ISO Personal Lines. “Excavating the line, fixing or replacing it, and repairing related damage can cost thousands of dollars. Our new endorsement is the kind of value-added enhancement that many consumers are looking for in today’s competitive homeowner
RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2020: NET SALES AND PROFITABILITY DECREASED FOLLOWING THE COVID-19 PANDEMIC; SUCCESSFUL MITIGATION RESULTED IN IMPROVED OPERATING CASH FLOW AND SIGNIFICANT REDUCTION IN INVENTORIES AND NET DEBT16.7.2020 16:00:00 CEST | Press release
Rapala VMC Corporation Half Year Financial Report July 16, 2020 at 5:00 p.m. RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2020: NET SALES AND PROFITABILITY DECREASED FOLLOWING THE COVID-19 PANDEMIC; SUCCESSFUL MITIGATION RESULTED IN IMPROVED OPERATING CASH FLOW AND SIGNIFICANT REDUCTION IN INVENTORIES AND NET DEBT January-June (H1) in brief: Net sales were 117.1 MEUR, down 17% from previous year (141.2). With comparable exchange rates sales were 17% down from previous year.Operating profit was -0.8 MEUR (11.4).Comparable operating profit* was 4.2 MEUR (12.0).Earnings per share was -0.12 EUR (0.17).Cash flow from operations was 13.4 MEUR (11.5).Inventories were 83.5 MEUR (108.6), down 23%.Net interest-bearing debt was 63.5 MEUR (104.1)Short-term outlook: End-consumer demand is currently on a good level in main markets, but it is still impossible to issue a financial guidance for 2020 due to lack of visibility and significant uncertainties related to the COVID-19 pandemic. * Excluding ma
Election Committee for Eolus Vind AB appointed16.7.2020 13:00:00 CEST | Press release
Hässleholm, Sweden, July 16, 2020 The Election committee consists of the following members: Hans-Göran Stennert, Chairman of the Board, Eolus Vind AB. Ingvar Svantesson, appointed by Domneåns Kraftaktiebolag. Hans Gydell, appointed by Hans-Göran Stennert. Hans Johansson, appointed by Åke Johansson. According to a decision of the Annual General Meeting of January 25, 2020, the Election Committee shall consist of one member appointed by each of the three largest shareholders and the Chairman of the Board. The appointment of the Election Committee has been carried out in such a manner that, Hans-Göran Stennert, Chairman of the Board of Eolus, on the basis of the Euroclear list of registered shareholders as of 31 May 2020, has contacted the largest known shareholders in the company, who have been invited to each propose a representative to the Election Committee. After such contacts, the Election Committee has been appointed. In total, approximately 34.3 percent of the votes are represente
Valberedning för Eolus Vind AB utsedd16.7.2020 13:00:00 CEST | Pressemelding
Hässleholm den 16 juli 2020 Valberedningen består av följande ledamöter: Hans-Göran Stennert, styrelseordförande i Eolus Vind AB. Ingvar Svantesson, utsedd av Domneåns Kraftaktiebolag. Hans Gydell, utsedd av Hans-Göran Stennert. Hans Johansson, utsedd av Åke Johansson. Enligt beslut på årsstämman den 25 januari 2020 skall valberedningen bestå av en ledamot utsedd av envar av de tre röstmässigt största ägarna jämte styrelseordföranden. Tillsättningen av valberedningen har skett genom att Eolus styrelseordförande Hans-Göran Stennert på grundval av bolagets, av Euroclear tillhandahållna, förteckning över registrerade aktieägare per den 31 maj 2020 kontaktat de för bolaget största kända ägarna, vilka uppmanats att var och en föreslå en representant till valberedningen. Efter sådana kontakter har valberedningen utsetts. Totalt representeras cirka 34,3 procent av rösterna i valberedningen. Valberedningens uppgift är att inför årsstämman 2021 framlägga förslag avseende antal styrelseledamöter
UPM permanently closes its Chapelle newsprint mill16.7.2020 10:00:00 CEST | Press release
(UPM, Helsinki, 16.07.2020 at 11:00 EET) – UPM will permanently cease production at its Chapelle newsprint mill in Grand-Couronne, France today. The consultation process with employee representatives was completed on June 15th, 2020 according to French legislation and approved by French authorities on July 15th, 2020. The closure impacts 228 people. UPM offers support to employees in order to alleviate the effects caused by staff reductions in relation to the closing of the mill. With the closure of the mill UPM will reduce a total of 240.000 tonnes of its newsprint paper capacity. “After UPM announced the intention to sell the Chapelle mill in September we started an active sales process and have been in discussions with interested parties since. However, we have not received binding offers by potential buyers. Consequently, we decided to close the mill, while at the same time working with employee representatives to mitigate the social impact on our employees. We remain committed to
Invitation to UPM’s webcast and press conference on half-year financial report 202016.7.2020 09:00:00 CEST | Press release
(UPM, Helsinki, 16 July 2020 at 10:00 EET) – UPM will publish its half-year financial report 2020 on 23 July 2020 at 09:30-10:00 EET. After publishing the report will be available on company's website at www.upm.com. A webcast and a conference call for analysts and investors in English language begins at 13:15 EET. UPM’s financial results will be presented by the President and CEO Jussi Pesonen and CFO Tapio Korpeinen. All participants can view the webcast online at www.upm.com or through this link, but participants who wish to ask questions must attend the conference call by dialling a number in the list below: Conference call title: UPM Interim Report for January – June 2020 International telephone numbers: Australia Toll: +61 284058549 Austria Toll: +43 19287907 Belgium Toll: +32 24035814 Denmark Toll: +45 35445577 Finland Toll: +358 981710310 France Toll: +33 170750711 Germany Toll: +49 6913803430 Hong Kong Toll: +852 30600225 India Toll: +91 2271279610 Ireland Toll: +353 14311252